Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML), Mixed Phenotype Acute Leukemia (MPAL), Chronic Myelomonocytic Leukemia (CMML) and Higher-Risk Myelodysplastic Syndrome (MDS

NCT04964518 is registered in ClinicalTrials.gov with Ascentage Pharma Group Inc. as lead sponsor.

NCT NCT04964518
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04964518 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML), Mixed Phenotype Acute Leukemia (MPAL), Chronic Myelomonocytic Leukemia (CMML) and Higher-Risk Myelodysplastic Syndrome (MDS
Lead sponsor
Ascentage Pharma Group Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 30, 2021
Completion date
October 30, 2024
Enrollment
24 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

aml, adult